Study: NCT06367166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venarus® (diosmin and hesperidin)
Description: Venarus® (diosmin and hesperidin) at a dosage of 1000 mg once daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venarus® (diosmin and hesperidin)
Description: Venarus® (diosmin and hesperidin) at a dosage of 1000 mg once daily for 6 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA) with miniphlebectomy
Description: Endovenous laser ablation will be performed under local and tumescent anesthesia, laser wavelength 1470nm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA) with miniphlebectomy
Description: Endovenous laser ablation will be performed under local and tumescent anesthesia, laser wavelength 1470nm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic compression
Description: All subject with varicose veins enrolled in the study will receive class 2 elastic compression (elastic stockings) after enrollment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic compression
Description: All subject with varicose veins enrolled in the study will receive class 2 elastic compression (elastic stockings) after enrollment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic compression
Description: All subject with varicose veins enrolled in the study will receive class 2 elastic compression (elastic stockings) after enrollment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic compression
Description: All subject with varicose veins enrolled in the study will receive class 2 elastic compression (elastic stockings) after enrollment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores
Description: The patients and healthy volunteers will undergo evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), Venous clinical severity (VCS) score, Visual Analog Scale (VAS) score and 20 item-ChronIc Venous dIsease quality-of-life Questionnaire (CIVIQ-20) at baseline, and 2, 3, and 6 months after enrollment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores
Description: The patients and healthy volunteers will undergo evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), Venous clinical severity (VCS) score, Visual Analog Scale (VAS) score and 20 item-ChronIc Venous dIsease quality-of-life Questionnaire (CIVIQ-20) at baseline, and 2, 3, and 6 months after enrollment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores
Description: The patients and healthy volunteers will undergo evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), Venous clinical severity (VCS) score, Visual Analog Scale (VAS) score and 20 item-ChronIc Venous dIsease quality-of-life Questionnaire (CIVIQ-20) at baseline, and 2, 3, and 6 months after enrollment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores
Description: The patients and healthy volunteers will undergo evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), Venous clinical severity (VCS) score, Visual Analog Scale (VAS) score and 20 item-ChronIc Venous dIsease quality-of-life Questionnaire (CIVIQ-20) at baseline, and 2, 3, and 6 months after enrollment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores
Description: The patients and healthy volunteers will undergo evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), Venous clinical severity (VCS) score, Visual Analog Scale (VAS) score and 20 item-ChronIc Venous dIsease quality-of-life Questionnaire (CIVIQ-20) at baseline, and 2, 3, and 6 months after enrollment